Notas de Prensa
-
2020-06-16DD MM YYYYPDFSanofi invests to make France its world class center of excellence in vaccine research and production
-
2020-05-25DD MM YYYYPDFSanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration
-
2020-04-24DD MM YYYYPDFFDA approves MenQuadfiTM the latest innovation in meningococcal (MenACWY) vaccination
-
2020-04-14DD MM YYYYPDFSanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
-
2020-04-06DD MM YYYYPDFSanofi successfully prices taps on outstanding bond issues for EUR 500 million
-
2020-04-03DD MM YYYYPDFAvailability of the Pre-quarterly Results Communication
-
2020-04-03DD MM YYYYPDFDupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
-
2020-03-27DD MM YYYYPDFSanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19
-
2020-03-27DD MM YYYYPDFSanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma
-
2020-03-02DD MM YYYYPDFFDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
-
2020-02-24DD MM YYYYPDFSanofi to create new industry leading European company to provide active pharmaceutical ingredients (API)
-
2020-01-28DD MM YYYYPDFFDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis